Earlier this month The SPC Blog posted this information concerning the ruling of the Oslo District Court on 10 February that Actavis’ valsartan/HCTZ product infringed Novartis’ Norwegian process patent NO 304 023 for a route of synthesis for valsartan as well as SPC/NO 1998 024. The judgment, which is now under appeal, was handed down on 10 February 2011; it deals inter alia with the question of the scope of Novartis’ Norwegian SPC in relation to valsartan (SPC/NO 1998 024).
Gunnar Sørlie (Partner, Bugge, Arentz-Hansen & Rasmussen) has now kindly sent this weblog a transcript of the original decision (in Norwegian) together with an unofficial translation into English. The SPC Blog thanks him very much for his kindness.
Friday, 18 March 2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment